AZD-1134

AZD-1134

Chemical structure of AZD-1134

AZD-1134 is an investigational drug developed by AstraZeneca for the treatment of various inflammatory conditions. It is a potent and selective Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK3, which are enzymes involved in the signaling pathways of several cytokines that play a key role in the immune response.

Mechanism of Action

AZD-1134 functions by inhibiting the activity of JAK1 and JAK3. These kinases are part of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which is critical for the signaling of many cytokines and growth factors. By blocking these kinases, AZD-1134 reduces the activity of pro-inflammatory cytokines, thereby modulating the immune response and reducing inflammation.

Therapeutic Applications

AZD-1134 is being investigated for its potential use in treating a variety of inflammatory and autoimmune diseases, including:

• Rheumatoid arthritis
• Psoriasis
• Inflammatory bowel disease

The drug's ability to selectively inhibit JAK1 and JAK3 makes it a promising candidate for conditions where these pathways are dysregulated.

Development and Clinical Trials

AZD-1134 is currently in the early stages of clinical development. Preclinical studies have demonstrated its efficacy in reducing inflammation in animal models. Clinical trials are ongoing to evaluate its safety, tolerability, and efficacy in humans.

Potential Side Effects

As with other JAK inhibitors, potential side effects of AZD-1134 may include:

• Increased risk of infections due to immunosuppression
• Elevated liver enzymes
• Changes in blood cell counts

Ongoing clinical trials aim to further elucidate the safety profile of AZD-1134.

Related Pages

• Janus kinase inhibitor
• AstraZeneca
• Cytokine
• Autoimmune disease